Large Inflow of Money Witnessed in Myriad Genetics

Myriad Genetics (MYGN) : On Thursday, The money flowed into the Myriad Genetics (MYGN) stock with an uptick to downtick ratio was recorded at 2.15. Transactions worth $2.03 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $0.94 million. The total money flow into the stock was $1.09 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $1.31 million of block transactions on upticks. The total money flow in block trades was $1.31 million. In terms of price action, Myriad Genetics (MYGN) traded down $0.43 during the session at $30.96. Compared to the previous days closing, the stock was down only by -1.37%. For the week, the stock is 0.62%, over previous weeks closing.


Myriad Genetics (MYGN) : 9 Wall Street analysts covering Myriad Genetics (MYGN) believe that the average level the stock could reach for the short term is $39.67. The maximum price target given is $50 and the minimum target for short term is around $25, hence the standard deviation is calculated at $7.87. The stock has recorded a 20-day Moving Average of 0.01% and the 50-Day Moving Average is 7.31%.

Myriad Genetics (NASDAQ:MYGN): The stock opened at $31.31 on Thursday but the bulls could not build on the opening and the stock topped out at $31.47 for the day. The stock traded down to $30.67 during the day, due to lack of any buying support eventually closed down at $30.88 with a loss of -1.62% for the day. The stock had closed at $31.39 on the previous day. The total traded volume was 871,995 shares.

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.